# Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

> **NCT06331728** · PHASE1 · COMPLETED · sponsor: **IgGenix Australia Pty Ltd** · enrollment: 32 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** IGNX001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06331728
- **Lead sponsor:** IgGenix Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-01
- **Primary completion:** 2025-11-06
- **Final completion:** 2025-11-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331728, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06331728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*